Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

被引:75
|
作者
Hamaoka, T. [2 ,3 ]
Costelloe, C. M. [4 ]
Madewell, J. E. [4 ]
Liu, P. [5 ]
Berry, D. A. [5 ]
Islam, R. [1 ]
Theriault, R. L. [1 ]
Hortobagyi, G. N. [1 ]
Ueno, N. T. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
bone diseases; breast neoplasms; diagnostic imaging; response assessment; FDG-PET; THERAPY; SCAN; TOMOGRAPHY; CARCINOMA; DIAGNOSIS; ONCOLOGY;
D O I
10.1038/sj.bjc.6605546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P = 0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. British Journal of Cancer (2010) 102, 651-657. doi:10.1038/sj.bjc.6605546 www.bjcancer.com Published online 26 January 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:651 / 657
页数:7
相关论文
共 50 条
  • [41] Targeted radiotherapy to the skeleton using 166Ho-DOTMP with autologous stem cell transplantation for patients with bone-only metastatic breast cancer
    Champlin, R
    Booser, D
    Rondon, G
    Williams, P
    Wendt, R
    Hortobagyi, G
    Ueno, N
    Podoloff, D
    BLOOD, 2004, 104 (11) : 395B - 395B
  • [42] The Relevance Of The Treatment The Prostate Primary Tumour In The Response To Radium-223 In Bone Metastatic Castration Resistant Prostate Cancer
    Costa, R. P.
    Serretta, V.
    Princiotta, A.
    Murabito, A.
    Tripoli, V.
    Licari, M.
    Scalici, G. C.
    Borsellino, N.
    Verderame, F.
    Gebbia, V.
    Sanfilippo, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S571 - S572
  • [43] Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer
    Khokher, Samina
    Qureshi, Muhammad Usman
    Chaudhry, Naseer Ahmad
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3213 - 3218
  • [44] The palliative effect of chemotherapy (CT) in metastatic breast cancer (MBC): Objective tumour response is associated with symptom (Sx) improvement
    Geels, P
    Eisenhauer, E
    Bezjak, A
    Zee, B
    Day, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S314 - S314
  • [45] Assessment of Tumour Response to Multimodalities of Treatment in Locally Advanced Breast Cancer Patients Using Comet Assay
    Santhy, K. S.
    Anupama
    Srividya, M.
    Mangayarkarasi, K. S.
    Arulraj, P.
    Usharani, M. V.
    INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2009, 9 (3-4) : 251 - 254
  • [46] Pathological Response Assessment to Neoadjuvant Chemotherapy in Breast Cancer Patients Utilizing Circulating Tumour Cells (CTCs)
    Huang, Yanmei
    Fitzgerald, Marie
    Spillane, Cathy
    Ffrench, Brendan
    O'Brien, Cathal
    Ruttle, Carmel
    Bogdanska, Anna
    Martin, Cara
    Mullen, Dorinda
    Kennedy, John
    O'Toole, Sharon
    O'Leary, John
    LABORATORY INVESTIGATION, 2018, 98 : 73 - 73
  • [47] Correlation between primary tumour and axillary lymph node response to neoadjuvant chemotherapy in breast cancer patients
    Kir, G.
    Olgun, Z. C.
    Okten, I. N.
    Ankarali, H.
    Girgin, R. B.
    Melemez, M. K.
    Alimoglu, O.
    VIRCHOWS ARCHIV, 2019, 475 : S19 - S19
  • [48] Pathological Response Assessment to Neoadjuvant Chemotherapy in Breast Cancer Patients Utilizing Circulating Tumour Cells (CTCs)
    Huang, Yanmei
    Fitzgerald, Marie
    Spillane, Cathy
    Ffrench, Brendan
    O'Brien, Cathal
    Ruttle, Carmel
    Bogdanska, Anna
    Martin, Cara
    Mullen, Dorinda
    Kennedy, John
    O'Toole, Sharon
    O'Leary, John
    MODERN PATHOLOGY, 2018, 31 : 73 - 73
  • [49] The relationship between deprivation, tumour stage and the systemic inflammatory response in patients with primary operable breast cancer
    Al Murri, AM
    Doughty, JC
    Lannigan, A
    Wilson, C
    McArdle, CS
    McMillan, DC
    BRITISH JOURNAL OF CANCER, 2004, 91 (06) : 1063 - 1065
  • [50] PREDICTORS OF TUMOUR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS: ARE PHYSICAL EXAMINATION AND ULTRASOUND ACCURATE ENOUGH?
    Toekes, A. M.
    Szentmartoni, G.
    Kulka, J.
    Toth, A. I.
    Szasz, A. M.
    Szekely, B.
    Dank, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 47 - 47